The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?

2020 ◽  
Author(s):  
Francesco Pierconti ◽  
Maurizio Martini ◽  
Vincenzo Fiorentino ◽  
Tonia Cenci ◽  
Sara Capodimonti ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Muscle Invasive

The relationship between ABO blood group type and tumor grade, stage, recurrence and progression in transitional cell carcinoma of the bladder: A preliminary report

2019 ◽  
Vol 13 (3) ◽  
pp. 205-209
Author(s):  
Deviprasad Tiwari ◽  
Harshit Garg ◽  
Brusabhanu Nayak ◽  
Prabhjot Singh ◽  
Amlesh Seth
Keyword(s):  
Bladder Cancer ◽  
Blood Group ◽  
Bladder Carcinoma ◽  
Statistical Significance ◽  
Transitional Cell ◽  
Abo Blood Group ◽  
Level Of Evidence ◽  
Muscle Invasive ◽  
Blood Grouping

Objectives: ABO blood grouping is a well-proven prognostic factor in many malignancies. This study aims to study the association and impact of ABO blood group on disease recurrence and progression in bladder carcinoma. Material and methods: Patients with bladder carcinoma undergoing transurethral resection of bladder tumor (TURBT) were studied prospectively for at least 1-year follow-up for recurrence and progression of the disease. Demographic profile along with blood group was noted. Results: Two hundred patients were included in the study and 194 patients were included in the final analysis. Muscle-invasive bladder cancer was present in 39 (20.1%) patients and the high-grade tumor was present in 88 (45.3%) patients. There was no statistical significance between the association of blood grouping and grade ( p=0.29) and stage of the disease ( p=0.20). During the follow-up period, there were 100 (64.5%) recurrences and 15 (9.7%) patients with non-muscle-invasive bladder carcinoma had progression. The association of blood group with recurrence ( p=0.66) and progression ( p=0.11) of disease was not statistically significant. Conclusion: There is no association between bladder cancer and ABO blood group in terms of grade and stage of the disease. The recurrence and progression of the disease did not differ significantly in different blood groups. Level of Evidence: 2b

scholarly journals Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-14 ◽  
Author(s):  
Enrique Redondo-Gonzalez ◽  
Leandro Nunes de Castro ◽  
Jesús Moreno-Sierra ◽  
María Luisa Maestro de las Casas ◽  
Vicente Vera-Gonzalez ◽  
...  
Keyword(s):  
Molecular Markers ◽  
Bladder Carcinoma ◽  
Clinical History ◽  
Prostatic Hyperplasia ◽  
Biological Behavior ◽  
Preoperative Imaging ◽  
Muscle Invasive ◽  
New Diagnosis

Bladder cancer occurs in the epithelial lining of the urinary bladder and is amongst the most common types of cancer in humans, killing thousands of people a year. This paper is based on the hypothesis that the use of clinical and histopathological data together with information about the concentration of various molecular markers in patients is useful for the prediction of outcomes and the design of treatments ofnonmuscle invasive bladder carcinoma(NMIBC). A population of 45 patients with a new diagnosis of NMIBC was selected. Patients withbenign prostatic hyperplasia(BPH),muscle invasive bladder carcinoma(MIBC),carcinoma in situ(CIS), and NMIBC recurrent tumors were not included due to their different clinical behavior. Clinical history was obtained by means of anamnesis and physical examination, and preoperative imaging and urine cytology were carried out for all patients. Then, patients underwent conventionaltransurethral resection(TURBT) and some proteomic analyses quantified the biomarkers (p53, neu, and EGFR). A postoperative follow-up was performed to detect relapse and progression. Clusterings were performed to find groups with clinical, molecular markers, histopathological prognostic factors, and statistics about recurrence, progression, and overall survival of patients with NMIBC. Four groups were found according to tumor sizes, risk of relapse or progression, and biological behavior. Outlier patients were also detected and categorized according to their clinical characters and biological behavior.

Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients

Cancer ◽  
1994 ◽  
Vol 74 (10) ◽  
pp. 2819-2827 ◽  
Author(s):  
Alan Pollack ◽  
Gunar K. Zagars ◽  
Colin P. Dinney ◽  
David A. Swanson ◽  
Andrew C. von Eschenbach
Keyword(s):  
Prognostic Factors ◽  
Bladder Carcinoma ◽  
Preoperative Radiotherapy ◽  
Long Term Follow Up ◽  
Muscle Invasive

The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma.

2021 ◽  
Author(s):  
Francesco Pierconti ◽  
Maurizio Martini ◽  
Tonia Cenci ◽  
Vincenzo Fiorentino ◽  
Luca Di Gianfrancesco ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
High Grade ◽  
Muscle Invasive

Role of imaging techniques in the diagnosis and follow-up of muscle-invasive bladder carcinoma

2018 ◽  
Vol 42 (7) ◽  
pp. 425-434
Author(s):  
A. Mesa ◽  
E. Nava ◽  
A. Fernández del Valle ◽  
B. Argüelles ◽  
R. Menéndez- del Llano ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Imaging Techniques ◽  
Muscle Invasive

743: Methylation of the E-Cadherin and the TIMP-3 Genes are Positive Prognostic Markers for Patients with Non-Muscle Invasive Bladder Carcinoma

2004 ◽  
Vol 171 (4S) ◽  
pp. 197-197
Author(s):  
Martin G. Friedrich ◽  
Gangning Liang ◽  
Marieta I. Toma ◽  
Daniel J. Weisenberger ◽  
Jonathan C. Cheng ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Prognostic Markers ◽  
Muscle Invasive ◽  
E Cadherin

scholarly journals Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience

2020 ◽  
Vol 26 (1) ◽  
Author(s):  
Vivek Sharma ◽  
Avinash P. S. Thakur ◽  
Vasantharaja Ramasamy ◽  
Pushpendra Kumar Shukla ◽  
Fanindra Singh Solanki ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adverse Effects ◽  
Bladder Carcinoma ◽  
Bladder Tumour ◽  
The Body ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Intravesical Bcg Therapy

Abstract Background Urothelial bladder carcinoma accounts for around 3.9% cases of all the male cancers in India. Non-muscle-invasive bladder carcinoma (NMIBC) is predominant group which constitute approximately three fourth of the urothelial bladder cancer. Intravesical BCG immunotherapy is the corner stone of today’s NMIBC management. However, as with any other therapy it has its own complications and its interruption due to these adverse effects is a major cause of suboptimal efficacy. The aim of this study was to assess the complications of intravesical BCG therapy and their management in NMIBC patients. Methods This was a retrospective descriptive study conducted between October 2016 and November 2019; a backward review of 149 patients with diagnosis of NMIBC that undergone intravesicle BCG therapy was performed. Patient’s demographical, clinical, diagnostic and procedural data regarding bladder tumour, BCG therapy, its complications and management were collected and analysed. Results Total 149 patients were analysed, comprising 116 males and 33 females. The mean age was of 57.2 ± 6.7 years. Total 85.23% were primary and 14.76% were recurrent tumours. Total 96 patients (64.42%) completed the planned course, while 53 (35.57%) interrupted. The reasons for BCG interruption includes adverse effects (15.4%), progression of disease (6.7%), disease refractory to BCG (4.6%) and disease recurrence during BCG (3.3%). Most of the adverse events occurred in first 6 months and most interruptions occurred after the induction period. Cystitis was the most common observed adverse effect seen in 39.6% patients. Frequency, urgency, haematuria were common presentation. Radical cystectomy was the most common (16.10%) further treatment with patients whose treatment was interrupted. Conclusion BCG is an indispensable therapy available for NMIBC, but it is associated with array of adverse effects and complications, which are the main reasons for poor compliance to BCG therapy. Although BCG-related complications can affect any organ in the body, potentially life-threatening systemic BCG-related infections are encountered in only < 5% of patients. There are some difficulties in diagnosis of the BCG complications because acid-fast staining, culture and PCR test are not always positive; tissue biopsies should be indicated sometimes to evaluate histopathology and presence of M. bovis. A persistently monitored multidisciplinary approach with high index of suspicion and prompt anti-TB therapy can help to derive the maximum benefits while keeping the complications at check.

scholarly journals Quality of Life following Chemoradiotherapy for Localized Muscle Invasive Bladder Carcinoma: A Systematic Review

2021 ◽  
pp. 1-13
Author(s):  
Ben-Max De Ruiter ◽  
Abel N. Keijzer ◽  
Maarten C.C.M. Hulshof ◽  
Adriaan D. Bins ◽  
Theo M. de Reijke ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Sexual Function ◽  
Bladder Carcinoma ◽  
Bowel Function ◽  
Definitive Treatment ◽  
Cochrane Library ◽  
Social And Emotional ◽  
Muscle Invasive ◽  
The Impact

BACKGROUND: Health related Quality of Life (HRQoL) is an important factor regarding treatment for localized Muscle Invasive Bladder Carcinoma (MIBC), as it may affect choice of treatment. The impact of chemoradiotherapy (CRT) for MIBC on HRQoL has not yet been well-established. OBJECTIVE: To systematically evaluate evidence regarding HRQoL as assessed by validated questionnaires after definitive treatment with CRT for localized MIBC. METHODS: We performed a critical review of PubMed/MEDLINE, EMBASE, and the Cochrane Library in October 2020. Two reviewers independently screened articles for eligibility and assessed the methodological quality of the included articles using Joanna Briggs Institute critical appraisal tools. A narrative synthesis was undertaken. RESULTS: Of 579 articles identified, 11 studies were eligible for inclusion, including three RCTs and 8 non-randomized studies, reporting on HRQoL data for 606 CRT patients. Global health declined at End of treatment (EoT), and recovered 3 months following treatment. Physical function declined from baseline at EoT and recovered between 3 and 24 months and was maintained at 5 years follow up. CRT had little effect on social and emotional function in the short-term, but HRQoL results in the long-term were lower compared to the general population. Urinary function declined from baseline at EoT, but returned to baseline at 6 months following CRT. After initial decline in bowel function, a complete return to baseline occurred 4 years following treatment. The majority of studies assessing sexual function showed no to little effect on sexual function. CONCLUSIONS: HRQoL recovers to baseline within 3 months to 2 years in almost all domains. The amount of available evidence regarding HRQoL following CRT for MIBC is limited and the quality of evidence is low.

Sign in / Sign up

Export Citation Format

Share Document